Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company Rigel Pharmaceuticals has earned a respected four-star ranking.
With that in mind, let's take a closer look at Rigel and see what CAPS investors are saying about the stock right now.
South San Francisco, Calif. (1996)
Chairman/CEO James Gower
Return on Equity (average, past 3 years)
$298.2 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 891 members who have rated Rigel believe the stock will outperform the S&P 500 going forward.
The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib ... as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.
As of the end of 2012, Rigel has about [$300M] in liquid assets to support a market cap of [$392M] at [Friday's] close. That's a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash.
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its strong four-star rating, Rigel may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Rigel Is Poised to Bounce Back originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.